SCOPE (Summit for Clinical Operations Executives) 2026

February 2, 2026
February 5, 2026
CET
Rosen Shingle Creek, Orlando, Florida (USA)

SCOPE brings together the full clinical research ecosystem for four high-impact days of discussion, strategy, and networking. SCOPE is the premier event for clinical trial innovation. In 2026, we’re building on that momentum by expanding coverage of in-demand topics focused on advancing solutions in trial planning, operations, innovation, and investment.

Stop by the Clario booth #916 and find out how we can help simplify your trials with integrated efficacy, safety and quality of life assessments across all phases, therapeutic areas and trial designs.

Session information:

Date: Wednesday, February 4, 2026

Time: 8:35 a.m. – 9:00 a.m. ET

Built for Trust: Responsibly Uniting Agentic and Generative AI to Optimize Data Quality and Interpretation of Clinical Outcomes Assessments

The crossroads of data integrity, data consistency, and accurate interpretation are ripe for the application of both agentic and generative AI. Developing and operationalize such tools requires recognition of potential risks and adherence to a responsible-use framework specifically designed for the clinical trial paradigm. A case-study-based approach will be taken, with real-world examples, demonstrating how novel applications of AI can enhance clinical outcomes assessments, delivering results sponsors and regulators can trust.

Speakers

Todd Rudo, M.D.

Executive Vice President, Chief Medical Officer at Clario

Dr. Todd Rudo is EVP and Chief Medical Officer at Clario, providing medical and scientific leadership across the organization. He has nearly 20 years of clinical cardiology and pharmaceutical research experience, with a career predominantly focused on drug safety. Dr. Rudo has board certifications in cardiology, cardiac electrophysiology, nuclear cardiology, adult echocardiography and internal medicine. His team provides expert consulting to clients on scientific and regulatory strategy, and ensures Clario’s product portfolio is scientifically robust, generating high quality clinical trial endpoint data. Dr. Rudo has a particular interest in applying innovative technologies to improve the scientific rigor of clinical trials, while maintaining focus on the customer experience, including minimizing patient and site burden.

Alex-Boudreau-headshot

Alex Boudreau

Director of AI at Clario

Alex Boudreau is the Director of AI at Clario. He leads the company’s innovative Generative AI department and oversees the development of the company’s advanced multi-modal GenAI Platform, which encompasses cutting-edge cloud engineering, AI engineering, and foundational AI research. Alex previously pioneered Deep Learning speech analysis systems for automotive applications, led cloud-based enterprise fraud detection solutions, advanced conversational AI technologies, and groundbreaking projects in medical image analysis. His expertise in leading high-impact initiatives positions him uniquely to drive forward the boundaries of AI technology in the business world.

Meet with us at SCOPE 2026

Complete this form and we will reach out soon to schedule a time to connect at the event.

If you are a company wishing to collaborate with us, please stop by our booth during the conference to talk with our team.